Lynda Chin, MDProfessor, Executive Director Real-world Education, Detection and Intervention, The University of Texas System; Founder, CEO Apricity Health

An elected member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation, Dr. Chin is a world renowned cancer genomic scientist, a frequent speaker in national and international conferences including TEDMed, who has authored or co-authored hundreds of peer-reviewed publications. At Dana-Farber Cancer Institute where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard, Dr. Chin conducted research spanning mouse models of human cancers, cancer genomics, functional genomics and personalized medicine. Outside of her laboratory, Dr. Chin held multiple leadership positions in The Cancer Genome Atlas (TCGA) project in the U.S., including serving on the executive subcommittee and leading the development of Firehose pipeline as co-PI at the Broad Institute. Internationally, Dr. Chin has been active in the International Cancer Genome Consortium since its inception, currently sitting on the ICGC-ARGO Steering Committee and chairing its Phenomics Working Group.
In 2011, Dr. Chin joined MD Anderson Cancer Center as the founding chair of the Department of Genomic Medicine, with a mission to accelerate the translation of scientific advances and democratize the best care to patients outside of academic centers through technologies, data and analytics. As chair, she launched APOLLO (Adaptive Patient-Oriented Longitudinal Learning and Optimization), a workflow platform to facilitate patient-orieinted research, and TRA (Translational Research Accelerator), a big data platform built to integrate longitudinally research and clinical care data at MD Anderson. She also conceptualized and led the development of MD Anderson Oncology Expert Advisor© powered by IBM Watson to demonstrate how AI analytics could be responsibly developed to democratize knowledge for evidence-based care. In 2015, foreseeing the need for a new model to harness real-world health and health-related data, Dr. Chin created the Institute for Health Transformation as the Chief Innovation Officer for Health Affairs at the University of Texas System. She conceived and founded Project DOC (Diabetes Obesity Control) to re-imagine technology-enabled chronic disease management for the vulnerable populations who are unequally burdened. Collaborating with public and private entities across industries, engaging local stakeholders in communities from federally qualified health center to churches, Dr. Chin established an industry-first digitally connected health data and care delivery ecosystem in one of the poorest communities in South Texas to implement REDI (Real-world Education, early Detection and Intervention), a framework that extends the concept of PCHM (Patient-Centered Medical Home) to deliver technology-enabled and data-informed chronic disease management in an ecosystem.
A mother of 3 teenagers, Dr. Chin is also an entrepreneur who has founded or co-founded cancer therapeutics, biomarker and AI companies. Apricity Health, her latest initiative, is an insight company developing digital therapeutics to improve effectiveness of real-world care, by putting world-class specialty expertise in the hands of practicing physicians around the world, starting with management of treatment-related toxicities in cancer patients receiving immuno-oncology therapies.

Lynda Chin, MDProfessor, Executive Director Real-world Education, Detection and Intervention, The University of Texas System; Founder, CEO Apricity Health

An elected member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation, Dr. Chin is a world renowned cancer genomic scientist, a frequent speaker in national and international conferences including TEDMed, who has authored or co-authored hundreds of peer-reviewed publications. At Dana-Farber Cancer Institute where she was a professor at Harvard Medical School and a senior associate member at the Broad Institute of MIT and Harvard, Dr. Chin conducted research spanning mouse models of human cancers, cancer genomics, functional genomics and personalized medicine. Outside of her laboratory, Dr. Chin held multiple leadership positions in The Cancer Genome Atlas (TCGA) project in the U.S., including serving on the executive subcommittee and leading the development of Firehose pipeline as co-PI at the Broad Institute. Internationally, Dr. Chin has been active in the International Cancer Genome Consortium since its inception, currently sitting on the ICGC-ARGO Steering Committee and chairing its Phenomics Working Group.
In 2011, Dr. Chin joined MD Anderson Cancer Center as the founding chair of the Department of Genomic Medicine, with a mission to accelerate the translation of scientific advances and democratize the best care to patients outside of academic centers through technologies, data and analytics. As chair, she launched APOLLO (Adaptive Patient-Oriented Longitudinal Learning and Optimization), a workflow platform to facilitate patient-orieinted research, and TRA (Translational Research Accelerator), a big data platform built to integrate longitudinally research and clinical care data at MD Anderson. She also conceptualized and led the development of MD Anderson Oncology Expert Advisor© powered by IBM Watson to demonstrate how AI analytics could be responsibly developed to democratize knowledge for evidence-based care. In 2015, foreseeing the need for a new model to harness real-world health and health-related data, Dr. Chin created the Institute for Health Transformation as the Chief Innovation Officer for Health Affairs at the University of Texas System. She conceived and founded Project DOC (Diabetes Obesity Control) to re-imagine technology-enabled chronic disease management for the vulnerable populations who are unequally burdened. Collaborating with public and private entities across industries, engaging local stakeholders in communities from federally qualified health center to churches, Dr. Chin established an industry-first digitally connected health data and care delivery ecosystem in one of the poorest communities in South Texas to implement REDI (Real-world Education, early Detection and Intervention), a framework that extends the concept of PCHM (Patient-Centered Medical Home) to deliver technology-enabled and data-informed chronic disease management in an ecosystem.
A mother of 3 teenagers, Dr. Chin is also an entrepreneur who has founded or co-founded cancer therapeutics, biomarker and AI companies. Apricity Health, her latest initiative, is an insight company developing digital therapeutics to improve effectiveness of real-world care, by putting world-class specialty expertise in the hands of practicing physicians around the world, starting with management of treatment-related toxicities in cancer patients receiving immuno-oncology therapies.

closepopup
Prasun J. Mishra, MSc, PhDFounding President and CEO AAPM; Founder & CEO, Agility Pharma; Founder, MetaImmune, Inc.

Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the founder and CEO of Agility Pharmaceuticals (Agility), based in San Francisco Bay Area, CA. Agility pharma is one of the leading artificial intelligence (AI)-driven pharmaceutical companies, as evident by key partnerships, recognition by scientific and tech community. He is also the founder of MetaImmune inc., an immunotherapy company, focused on finding curative therapies for cancer through targeting tumor-immune interactions. He is also founding president and CEO of American Association for Precision Medicine (AAPM). He is best known for discovering the role for noncoding RNA in drug resistance and pharmacogenomics. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and mechanisms of action/resistance of both new and established drugs, which has facilitated development of rational drug combinations in the clinic. His research work has been recognized globally by numerous awards and honors. In addition to his professional commitments, Dr. Mishra also gives back to his local biotech community by serving as an advisor to several companies in the San Francisco Bay Area to advance their R&D and funding strategy. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Project Zygote and California Life Sciences Association, to help grow California’s life sciences innovation ecosystem. Moreover, discoveries lead by Dr. Mishra and his teams have contributed to the development of new and viable strategies of prevention, diagnosis and treatment of patients in the clinic.

Prasun J. Mishra, MSc, PhDFounding President and CEO AAPM; Founder & CEO, Agility Pharma; Founder, MetaImmune, Inc.

Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the founder and CEO of Agility Pharmaceuticals (Agility), based in San Francisco Bay Area, CA. Agility pharma is one of the leading artificial intelligence (AI)-driven pharmaceutical companies, as evident by key partnerships, recognition by scientific and tech community. He is also the founder of MetaImmune inc., an immunotherapy company, focused on finding curative therapies for cancer through targeting tumor-immune interactions. He is also founding president and CEO of American Association for Precision Medicine (AAPM). He is best known for discovering the role for noncoding RNA in drug resistance and pharmacogenomics. Moreover, his passion for drug development and precision medicine has led to identification of new drug targets, biomarkers, companion diagnostics, and mechanisms of action/resistance of both new and established drugs, which has facilitated development of rational drug combinations in the clinic. His research work has been recognized globally by numerous awards and honors. In addition to his professional commitments, Dr. Mishra also gives back to his local biotech community by serving as an advisor to several companies in the San Francisco Bay Area to advance their R&D and funding strategy. The companies that he has advised have raised multimillion dollars. Notably, he serves as a mentor and advisor to startup accelerators such as IndieBio, Project Zygote and California Life Sciences Association, to help grow California’s life sciences innovation ecosystem. Moreover, discoveries lead by Dr. Mishra and his teams have contributed to the development of new and viable strategies of prevention, diagnosis and treatment of patients in the clinic.

closepopup
Rashmi GopinathPartner at M12 (fka Microsoft Ventures)

Rashmi leads enterprise software investments for M12 in the Bay Area. She brings a combination of strong venture capital and startup operating experience. Previously, Rashmi was an Investment Director at Intel Capital focused on investing in cloud, infrastructure, and big data companies. She also led global business development for high-growth startups Couchbase and BlueData. Prior to that, she held business development and product development positions at GE and Oracle. Rashmi has an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor of Engineering from the University of Mumbai in India.

Rashmi GopinathPartner at M12 (fka Microsoft Ventures)

Rashmi leads enterprise software investments for M12 in the Bay Area. She brings a combination of strong venture capital and startup operating experience. Previously, Rashmi was an Investment Director at Intel Capital focused on investing in cloud, infrastructure, and big data companies. She also led global business development for high-growth startups Couchbase and BlueData. Prior to that, she held business development and product development positions at GE and Oracle. Rashmi has an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor of Engineering from the University of Mumbai in India.

closepopup
Ming Jack Po, MD, PhDProduct Manager at Google Brain and Google Cloud

Jack Po is a product manager at Google working on medical brain and health cloud. Previously, he has also spent time in Google’s search unit working on health related queries. Prior to Google, Jack spent a decade working in venture capital and medical devices. Jack also has a strong interest in health care policy and global health, and he has served in various advisory capacities to NGOs / ministries of health on the scale up of healthcare and education systems.

Ming Jack Po, MD, PhDProduct Manager at Google Brain and Google Cloud

Jack Po is a product manager at Google working on medical brain and health cloud. Previously, he has also spent time in Google’s search unit working on health related queries. Prior to Google, Jack spent a decade working in venture capital and medical devices. Jack also has a strong interest in health care policy and global health, and he has served in various advisory capacities to NGOs / ministries of health on the scale up of healthcare and education systems.

closepopup
Sara I. Pai, MD, PhDDirector, Translational Research, Harvard Medical School, Mass General Hospital

Dr. Sara Pai is an Associate Professor at Harvard Medical School and the Massachusetts General Hospital. She graduated Summa Cum Laude from Dartmouth College with a major in Biochemistry and Molecular Biology. After graduating Dartmouth, she completed the MD/PhD program at Johns Hopkins University School of Medicine in which she obtained her PhD training in cancer immunology and vaccines. After completing her residency in Otolaryngology-Head and Neck Surgery at Johns Hopkins Hospital, she joined its faculty in 2007 where she led a therapeutic HPV vaccine clinical trial which was supported by the Head and Neck Cancer SPORE grant. In 2014, she joined the faculty in the Department of Surgery at the Massachusetts General Hospital. Her research interests focus on better understanding how human papillomavirus (HPV) can evade the immune system and strategies that can be applied to reactivate the host immune response against the virus through vaccines and immune modulatory drugs. She leads several HPV related investigator-initiated clinical immunotherapy trials and has a research laboratory that is supported by the National Institutes of Health (NIH) as well as industry. She serves on grant and strategic review panels at the NIH and international government sponsored programs in the UK, Hong Kong, and Portugal. She is on the editorial board of lead scientific journals as well as serves on the advisory boards for several pharmaceutical companies.

Sara I. Pai, MD, PhDDirector, Translational Research, Harvard Medical School, Mass General Hospital

Dr. Sara Pai is an Associate Professor at Harvard Medical School and the Massachusetts General Hospital. She graduated Summa Cum Laude from Dartmouth College with a major in Biochemistry and Molecular Biology. After graduating Dartmouth, she completed the MD/PhD program at Johns Hopkins University School of Medicine in which she obtained her PhD training in cancer immunology and vaccines. After completing her residency in Otolaryngology-Head and Neck Surgery at Johns Hopkins Hospital, she joined its faculty in 2007 where she led a therapeutic HPV vaccine clinical trial which was supported by the Head and Neck Cancer SPORE grant. In 2014, she joined the faculty in the Department of Surgery at the Massachusetts General Hospital. Her research interests focus on better understanding how human papillomavirus (HPV) can evade the immune system and strategies that can be applied to reactivate the host immune response against the virus through vaccines and immune modulatory drugs. She leads several HPV related investigator-initiated clinical immunotherapy trials and has a research laboratory that is supported by the National Institutes of Health (NIH) as well as industry. She serves on grant and strategic review panels at the NIH and international government sponsored programs in the UK, Hong Kong, and Portugal. She is on the editorial board of lead scientific journals as well as serves on the advisory boards for several pharmaceutical companies.

closepopup
Rave Harpaz, PhDSenior Director, Research & Data Science at Oracle Health Sciences

Rave Harpaz is a Senior Director Research & Data Science at Oracle Health Sciences at Oracle Health Sciences. Previously, Rave was a Research Scientist at the Center for Biomedical Informatics Research, Stanford University (2012- 2014), a post-doctoral fellow at the Department of Biomedical Informatics Columbia University (2009-2012), and a quantitative risk modeling analyst at Merrill Lynch (2007-2009). Rave holds a PhD in Computer Science from the City University of New York (2008) specializing in the area of unsupervised Machine Learning, and holds a Law degree (LLB) from Tel-Aviv University, Israel.
Rave’s current research is focused on methods to extract and combine drug safety information from several data sources including: health records, spontaneous reports, the biomedical literature, biological databases, and the social media

Rave Harpaz, PhDSenior Director, Research & Data Science at Oracle Health Sciences

Rave Harpaz is a Senior Director Research & Data Science at Oracle Health Sciences at Oracle Health Sciences. Previously, Rave was a Research Scientist at the Center for Biomedical Informatics Research, Stanford University (2012- 2014), a post-doctoral fellow at the Department of Biomedical Informatics Columbia University (2009-2012), and a quantitative risk modeling analyst at Merrill Lynch (2007-2009). Rave holds a PhD in Computer Science from the City University of New York (2008) specializing in the area of unsupervised Machine Learning, and holds a Law degree (LLB) from Tel-Aviv University, Israel.
Rave’s current research is focused on methods to extract and combine drug safety information from several data sources including: health records, spontaneous reports, the biomedical literature, biological databases, and the social media

closepopup
Slava Akmaev, Ph.D.Senior VP & Chief Analytics Officer at BERG

Slava Akmaev, Ph.D., is the Senior VP and Chief Analytics Officer at BERG. Dr. Akmaev is the industry leader in AI and machine learning applications in life sciences and healthcare. He heads the BERG Analytics business division and is the chief architect of Bayesian Artificial Intelligence software, bAIcis®. Dr. Akmaev is an avid advocate for data driven research and promotes wider utility of advanced mathematical modeling techniques in pharmaceutical and clinical research. Prior to his role at BERG, Dr. Akmaev spent a decade at Genzyme R&D and the CLIA diagnostic laboratory, Genzyme Genetics. He led the development and commercialization of novel multi-omic panel diagnostics in oncology and prenatal medicine. Dr. Akmaev has published numerous peer-reviewed manuscripts in genomics, systems biology, biochemistry and human genetics. He is a frequent speaker at AI, analytics and precision medicine conferences. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.

Slava Akmaev, Ph.D.Senior VP & Chief Analytics Officer at BERG

Slava Akmaev, Ph.D., is the Senior VP and Chief Analytics Officer at BERG. Dr. Akmaev is the industry leader in AI and machine learning applications in life sciences and healthcare. He heads the BERG Analytics business division and is the chief architect of Bayesian Artificial Intelligence software, bAIcis®. Dr. Akmaev is an avid advocate for data driven research and promotes wider utility of advanced mathematical modeling techniques in pharmaceutical and clinical research. Prior to his role at BERG, Dr. Akmaev spent a decade at Genzyme R&D and the CLIA diagnostic laboratory, Genzyme Genetics. He led the development and commercialization of novel multi-omic panel diagnostics in oncology and prenatal medicine. Dr. Akmaev has published numerous peer-reviewed manuscripts in genomics, systems biology, biochemistry and human genetics. He is a frequent speaker at AI, analytics and precision medicine conferences. Dr. Akmaev holds a Ph.D. in Applied Mathematics from the University of Colorado at Boulder.

closepopup
Tatyana KanzaveliFounder & CEO of Open Health Network; Blockchain In Healthcare

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.

She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.

Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.

Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.

Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.

Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.

Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

Tatyana KanzaveliFounder & CEO of Open Health Network; Blockchain In Healthcare

Tatyana Kanzaveli has gone from a programmer to senior executive at Big 5 to founder and CEO of a startup company along her 20 year career,recognized as a thought leader, mentor for her ability to guide Fortune 500 and startup companies through business challenges.

She’s worked for major companies like PricewaterhouseCoopers and Fujitsu and startups in the early days of the Web.

Tatyana has personally helped companies jump from 0 to millions in revenue even during the toughest economic times. She opened new verticals and markets.

Today she is the founder and CEO of Open Health Network, the startup in a Big Data/Healthcare space. She is a mentor at 500Startups and Richard Branson Entrepreneurs Centre and serves on boards for private companies. She also is licensee and organizer of highly notable TEDxBayArea conferences, she is a frequent speaker at US and International conferences on innovation, entrepreneurship and digital health.

Tatyana has been featured in the White House blog , spoke at the United Nations, presented at the first White House Demo Day hosted by the President Obama.

Tatyana has been recognized as one of the top 10 Influential Women in Healthcare IT in 2015.

Tatyana was USSR chess champion, played in the same team with Gary Kasparov, she loves to cook and kayak.

closepopup
Uli K. Chettipally, MD.Co-founder & CTO, CREST Network, Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

Uli K. Chettipally, MD.Co-founder & CTO, CREST Network, Kaiser Permanente

Dr. Chettipally is a speaker, emergency physician, researcher, and an innovator. He is passionate about the technology-enabled care that can decrease the burden on physicians and increase the value for patients. As the Co-founder and Chief Technology Officer of CREST Network, he designed, developed and implemented a clinical decision support platform to deliver real-time guidance at the point of care, to decrease the cognitive burden on physicians and improve patient outcomes in 21 hospitals. He received the "Pioneer Award" from Kaiser Permanente Innovations and "Morris F. Collen Research Award" from The Permanente Medical Group for his groundbreaking work. His other roles include President, Society of Physician Entrepreneurs, San Francisco Bay Area chapter; Assistant Clinical Professor of Medicine at the University of California, San Francisco; and is the Secretary/Treasurer, San Mateo County Medical Association.

closepopup

Speaker Highlight at DANS 2019

Speaker Highlight at DANS 2019